WCN26-5317 POPULATION PK/PD MODELING TO ASSESS ETHNIC SENSITIVITY IN THE CLINICAL DEVELOPMENT OF SEFAXERSEN

Read full text Summarise with VIRAT
Authors: Sylvie Retout, Takakazu Sato, Qingqing Xiao, Félix Jaminion, Vishal Duggal, Nikhil Kamath, Jeannette Lo, Nelson Guerreiro
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Dysregulation of the complement alternative pathway (AP) contributes to progression of IgA nephropathy (IgAN). Elevated Factor B (FB), a key AP protein, is linked to proteinuria and kidney function decline. Sefaxersen is a GalNAc-conjugated antisense oligonucleotide (ASO) designed for targeted hepatic delivery to suppress FB production. It is the first AP mRNA-targeting therapy in late-stage development for IgAN. In Phase 1 and 2 studies, sefaxersen was well tolerated and markedly reduced systemic FB and AH50, a measure of alternative complement pathway activity.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Complement system in diseases Statistical Methods in Clinical Trials

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
106239–106239
Publication date
25 March 2026
Language
EN